Postoperative recurrence and the role of adjuvant chemotherapy in patients with pulmonary large-cell neuroendocrine carcinoma

Journal of Thoracic and Cardiovascular Surgery

Volumn 138, Issue 2, 2009, Pages 446-453

  Iyoda, Akira ^a   Hiroshima, Kenzo ^a   Moriya, Yasumitsu ^a   Iwadate, Yasuo ^a   Takiguchi, Yuichi ^a   Uno, Takashi ^a   Nakatani, Yukio ^a   Yoshino, Ichiro ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LARGE CELL NEUROENDOCRINE CARCINOMA; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEUROENDOCRINE TUMOR; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, LARGE CELL; CARCINOMA, NEUROENDOCRINE; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS;

EID: 67651087283     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2008.12.037     Document Type: Article

References (25)

1. In: Travis W.D., Colby T.V., Corrin B., Shimosato Y., and Brambilla E. (Eds). Histological typing of lung and pleural tumours. World Health Organization International Histological Classification of Tumors, XIII. 3rd ed (1999), Springer-Verlag, Berlin/Heidelberg
2. Iyoda A., Hiroshima K., Nakatani Y., and Fujisawa T. Pulmonary large cell neuroendocrine carcinoma: its place in the spectrum of pulmonary carcinoma. Ann Thorac Surg 84 (2007) 702-707
3. Iyoda A., Hiroshima K., Toyozaki T., Haga Y., Fujisawa T., and Ohwada H. Clinical characterization of pulmonary large cell neuroendocrine carcinoma and large cell carcinoma with neuroendocrine morphology. Cancer 91 (2001) 1992-2000
4. Asamura H., Kameya T., Matsuno Y., Noguchi M., Tada H., Ishikawa Y., et al. Neuroendocrine neoplasms of the lung: a prognostic spectrum. J Clin Oncol 24 (2006) 70-76
5. Iyoda A., Hiroshima K., Moriya Y., Mizobuchi T., Otsuji M., Sekine Y., et al. Pulmonary large cell neuroendocrine carcinoma demonstrates high proliferative activity. Ann Thorac Surg 77 (2004) 1891-1895
6. Iyoda A., Hiroshima K., Baba M., Saitoh Y., Ohwada H., and Fujisawa T. Pulmonary large cell carcinomas with neuroendocrine features are high-grade neuroendocrine tumors. Ann Thorac Surg 73 (2002) 1049-1054
7. Onuki N., Wistuba II, Travis W.D., Virmani A.K., Yashima K., Brambilla E., et al. Genetic changes in the spectrum of neuroendocrine lung tumors. Cancer 85 (1999) 600-607
8. Jones M.H., Virtanen C., Honjoh D., Miyoshi T., Satoh Y., Okumura S., et al. Two prognostically significant subtypes of high-grade lung neuroendocrine tumours independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles. Lancet 363 (2004) 775-781
9. Hiroshima K., Iyoda A., Shibuya K., Haga Y., Toyozaki T., Iizasa T., et al. Genetic alterations in early-stage pulmonary large cell neuroendocrine carcinoma. Cancer 100 (2004) 1190-1198
10. Iyoda A., Hiroshima K., Toyozaki T., Haga Y., Baba M., Fujisawa T., et al. Adjuvant chemotherapy for large cell carcinoma with neuroendocrine features. Cancer 92 (2001) 1108-1112
11. Yamazaki S., Sekine I., Matsuno Y., Takei H., Yamamoto N., Kunitoh H., et al. Clinical responses of large cell neuroendocrine carcinoma of the lung to cisplatin-based chemotherapy. Lung Cancer 49 (2005) 217-223
12. Iyoda A., Hiroshima K., Moriya Y., Takiguchi Y., Sekine Y., Shibuya K., et al. Prospective study of adjuvant chemotherapy for pulmonary large cell neuroendocrine carcinoma. Ann Thorac Surg 82 (2006) 1802-1807
13. Rossi G., Cavazza A., Marchioni A., Longo L., Migaldi M., Sartori G., et al. Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung. J Clin Oncol 23 (2005) 8774-8785
14. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000) 205-216
15. Travis W.D., Rush W., Flieder D.B., Falk R., Fleming M.V., Gal A.A., et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol 22 (1998) 934-944
16. Paci M., Cavazza A., Annessi V., Putrino I., Ferreri G., De Franco S., et al. Large cell neuroendocrine carcinoma of the lung: a 10-year clinicopathologic retrospective study. Ann Thorac Surg 77 (2004) 1163-1167
17. Battafarano R.J., Fernandez F.G., Ritter J., Meyers B.F., Guthrie T.J., Cooper J.D., et al. Large cell neuroendocrine carcinoma: an aggressive form of non-small cell lung cancer. J Thorac Cardiovasc Surg 130 (2005) 166-172
18. Skuladottir H., Hirsch F.R., Hansen H.H., and Olsen J.H. Pulmonary neuroendocrine tumors: incidence and prognosis of histological subtypes. A population-based study in Denmark. Lung Cancer 37 (2002) 127-135
19. Mehta M.P., Tsao M.N., Whelan T.J., Morris D.E., Hayman J.A., Flickinger J.C., et al. The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys 63 (2005) 37-46
20. Ishikawa A., Motohashi S., Ishikawa E., Fuchida H., Higashino K., Otsuji M., et al. A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res 11 (2005) 1910-1917
21. Okada M., Koike T., Higashiyama M., Yamato Y., Kodama K., and Tsubota N. Radical sublobar resection for small-sized non-small cell lung cancer: a multicenter study. J Thorac Cardiovasc Surg 132 (2006) 769-775
22. Kamiyama H., Ikeya T., Suda K., Murai K., Aoyama K., and Hoshi E. Second primary digestive cancer after resection of lung cancer. Surg Today 34 (2004) 577-580
23. Battafarano R.J., Force S.D., Meyers B.F., Bell J., Guthrie T.J., Cooper J.D., et al. Benefits of resection for metachronous lung cancer. J Thorac Cardiovasc Surg 127 (2004) 836-842
24. Johnson B.E. Second lung cancers in patients after treatment for an initial lung cancer. J Natl Cancer Inst 90 (1998) 1335-1345
25. van den Belt-Dusebout A.W., de Wit R., Gietema J.A., Horenblas S., Louwman M.W., Ribot J.G., et al. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 25 (2007) 4370-4378